Supernus Pharmaceuticals Inc
SUPN
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
110.9% upsideUndervalued by 110.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.68 Billion |
|---|---|
| Enterprise Value | $2.54 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.68 |
| Beta | 0.57 |
| Outstanding Shares | 57,647,548 |
Return
| Return on Equity | -2.69% |
|---|---|
| Return on Assets | -1.93% |
| Return on Invested Capital | -6.89% |
Valuation & Multiples
| P/E Ratio | -91.75 |
|---|---|
| PEG | 113.81 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 2.45 |
| Enterprise Value to Revenue | 0.01 |
| Enterprise Value to EBIT | -32.65 |
| Enterprise Value to Net Income | -88 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6564▲ 80.35% |
|---|---|
| Total Calls | 63,571▼ 46.48% |
| Total Puts | 105,300▲ 3.95% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 103.13%▲ 1.86% |
|---|---|
| Total Invested | $3.01B▲ 5.92% |
| Investors Holding | 332▼ 9.00% |
ESG Score
No data
About Supernus Pharmaceuticals Inc
CEO: Jack Khattar Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy directly impact profitability, and its influence over Medicare pricing is a major determinant of revenue for pharmaceutical companies like Supernus.
This committee directly regulates the FDA and NIH, which are critical agencies for pharmaceutical companies. Its oversight of drug approval processes and the broader health sector directly drives the stock performance and operational environment for Supernus.
Intellectual property (patents) is foundational to the pharmaceutical industry's business model. This committee's oversight of antitrust laws and intellectual property rights directly impacts Supernus's ability to protect its products and engage in M&A activities.